Vera Therapeutics announces positive per-protocol analysis from Phase 2b ORIGIN trial of atacicept in IgA nephropathy

Vera Therapeutics, Inc.

At Week 24, atacicept 150 mg achieved 41% mean reduction in proteinuria and 34% delta vs placebo (p=0.025).
At Week 36 interim, atacicept 150 mg showed 47% mean reduction from baseline and 48% delta vs placebo.
Serious treatment-emergent AEs occurred in 2% of atacicept patients vs 9% in placebo; discontinuation rate 1%.
Company plans to advance atacicept into pivotal Phase 3 in first half of 2023, after FDA discussions.
Prespecified per-protocol analysis excluded 14 patients with protocol violations identified by blinded CRO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.